Small molecule inhibitors of Src family kinases

Drugs of the Future

Volumn 25, Issue 7, 2000, Pages 717-736

  Boschelli, D H ^a   Boschelli, F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AG 99; AGROCLAVINE; ANTHRAQUINONE DERIVATIVE; CGP 77675; DAMNACANTHAL; ELLAGIC ACID; ERBSTATIN; GELDANAMYCIN; HERBIMYCIN; KAN 104141; KAN 108308; KF 25706; LAVENDUSTIN A; OXIME DERIVATIVE; PAECILOQUINONE A; PD 166285; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUERCETIN; QUERCETIN DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; RADICICOL; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 61651;

BIOGENESIS; CANCER; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033794834     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.07.661381     Document Type: Review

References (243)

1. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
2. Signal transduction via the histidyl-aspartyl phosphorelay
3. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification
4. Signalling pathways in two-component phosphorelay systems
5. Vertebrate non-receptor protein-tyrosine kinase families
6. Cytokine signaling through nonreceptor tyrosine kinases
7. Src family protein tyrosine kinases: Cooperating with growth factor and adhesion signaling pathways
8. Viral oncogenes
9. Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine
10. Transforming gene product of Rous sarcoma virus phosphorylate tyrosine
11. Cell transformation by the viral src oncogene
12. A normal cell protein similar in structure and function to the avian sarcoma virus transforming gene product
13. Low level of cellular protein phosphorylation by nontransforming overproduced p60c-src
14. Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src)
15. Homology between phosphotyrosine acceptor site of human c-abl and viral oncogene products
16. Avian sarcoma virus Y73 genome sequence and structural similarity of its transforming gene product to that of Rous sarcoma virus
17. Characterization of cDNA clones for the human c-yes gene
18. Cellular proteins homologous to the viral yes gene product
19. Gene product of v-fgr onc: Hybrid protein containing a portion of actin and a tyrosine-specific protein kinase
20. Primary structure of the human fgr proto-oncogene product p55c-fgr
21. Structure, expression, and chromosomal location of the human c-fgr gene
22. Identification and characterization of p59fyn (a src-like protein tyrosine kinase) in normal and polyoma virus transformed cells
23. Yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family
24. A lymphoma cell line expressing elevated levels of tyrosine protein kinase activity
25. A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA
26. Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas
27. Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells
28. The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lck
29. Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells
30. A novel Yes-related kinase, Yrk, is expressed at elevated levels in neural and hematopoietic tissues
31. Regulation, substrates and functions of src
32. The many faces of Src: Multiple functions of a prototypical tyrosine kinase
33. Leukocyte protein tyrosine kinases: Potential targets for drug discovery
34. The p60c-src family of protein-tyrosine kinases: Structure, regulation, and function
35. Knockouts of Src-family kinases: Stiff bones, wimpy T cells, and bad memories
36. Src-related protein tyrosine kinases in hematopoiesis
37. Structures of Src-family tyrosine kinases
38. Structure-function relationships in Src family and related protein tyrosine kinases
39. A short sequence in the p60src N terminus is required for p6Osrc myristylation and membrane association and for cell transformation
40. Processing of p60v-src to its myristylated membrane-bound form
41. The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: Lysine 7 is a critical determinant
42. Palmitoylation of multiple Src-family kinases at a homologous N-terminal motif
43. S-Acylation of LCK protein tyrosine kinase is essential for its signalling function in T lymphocytes
44. Fatty acylation of proteins: New insights into membrane targeting of myristoylated and palmitoylated proteins
45. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps
46. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src
47. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis
48. Three-dimensional structure of the tyrosine kinase c-Src
49. The 2.35 Angstrom crystal structure of the inactivated form of chicken Src: A dynamic molecule with multiple regulatory interactions
50. Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: The intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated
51. Tyr527 is phosphorylated in pp60c-src: Implications for regulation
52. Phosphorylation of c-Src on tyrosine 527 by another protein tyrosine kinase
53. Crystal structure of HcK in complex with a Src family-selective tyrosine kinase inhibitor
54. Src autoinhibition: Let us count the ways
55. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin
56. Transit of pp60v-src to the plasma membrane
57. CDC37 is required for p60v-src activity in yeast
58. The Ydj1 molecular chaperone facilitates formation of active p60v-src in yeast
59. Heat-shock protein hsp90 governs the activity of pp60v-src kinase
60. Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system
61. Role of the protein chaperone YDJ1 in establishing Hsp90-mediated signal transduction pathways
62. Cdc37 is a molecular chaperone with specific functions in signal transduction
63. p50(cdc37) Acting in concert with Hsp90 is required for Raf-1 function
64. The Hsp90-based chaperone system - Involvement in signal transduction from a variety of hormone and growth factor receptors
65. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases
66. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90
67. Hsp90-mediated folding of the lymphoid cell kinase p56lck
68. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
69. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
70. Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila
71. The SRC family protein tyrosine kinase p62(yes) controls polymeric IgA transcytosis in vivo
72. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
73. Requirements of pp60c-src expression for osteoclasts to form ruffled borders and to resorb bone in mice
74. Tyrosine phosphorylation of P130(Cas) is involved in actin organization in osteoclasts
75. Src family kinases are required for integrin but not PDGFR signal transduction
76. Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport
77. Association between the PDGF receptor and members of the src family of tyrosine kinases
78. pp60c-src Tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src
79. Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling
80. The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor
81. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases
82. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor
83. Activation of Src family members is not required for the platelet-derived growth factor beta receptor to initiate mitogenesis
84. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr(845) and Tyr(1101) is associated with modulation of receptor function
85. Phosphorylation of growth factor receptor binding protein-2 by pp60c-src tyrosine kinase
86. Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors
87. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells
88. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src
89. Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor
90. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts
91. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
92. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeabllity
93. Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation
94. Lck associates with and is activated by Kit in a small cell lung cancer cell line: Inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1
95. c-Src Kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells
96. Cellular functions regulated by Src family kinases
97. 2-adrenergic receptor internalization and mitogen-activated protein kinase signaling
98. Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts
99. Regulation of tyrosine kinase cascades by G-protein-coupled receptors
100. The role of pp60c-src in the regulation of calcium entry via store-operated calcium channels
101. Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src
102. Gastrin stimulates the formation of a p60Src/p125FAK complex upstream of the phosphatidylinositol 3-kinase signaling pathway
103. Agonist-dependent phosphorylation of the G protein-coupled receptor kinase 2 (GRK2) by Src tyrosine kinase
104. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts - Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases
105. 1 protein-coupled receptors in Madin-Darby canine kidney cells
106. Involvement of protein kinase C and Src family tyrosine kinase in Galpha(q/11)-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase
107. 2 adrenergic receptor Src protein kinase complexes
108. Constitutive activation of delayed-rectifier potassium channels by a src family tyrosine kinase in Schwann cells
109. Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain
110. Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors
111. Phosphorylation and cytoskeletal anchoring of the acetylcholine receptor by Src class protein-tyrosine kinases - Activation by rapsyn
112. 2 for fibroblast cell division
113. A target for Src in mitosis
114. Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src
115. Src and the control of cell division
116. 1 progression
117. Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex
118. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: Summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events
119. Signaling through focal adhesion kinase
120. Integrins and signal transduction pathways: The road taken
121. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets
122. Identification and characterization of a cytoskeleton-associated, epidermal growth factor sensitive pp60c-src substrate
123. Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix
124. Adhesion-induced tyrosine phosphorylation of the p130 src substrate
125. Src kinase plays an essential role in integrin-mediated tyrosine phosphorylation of Crk-associated substrate p130Cas
126. Signaling through focal adhesion kinase
127. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: A role for paxillin tyrosine phosphorylation
128. Activation of pp60c-src is necessary for human vascular smooth muscle cell migration
129. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis
130. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility
131. c-Src Kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells
132. pp60(c-src) Is required for cell locomotion regulated by the hyaluronan receptor RHAMM
133. Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion
134. Beta-catenin: A common target for the regulation of cell adhesion by Wnt-1 and Src signaling pathways
135. Growth factors and the kidney: Regulation of epithelial cell movement and morphogenesis
136. The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts
137. Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: Cooperation between src and HGF/Met in invasion
138. V-src kinase shifts the cadherin-based cell adhesion from the strong to the weak state and beta catenin is not required for the shift
139. Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells
140. Extracellular regulation of cancer invasion: The E-cadherin-catenin and other pathways
141. L-selectin activates the Ras pathway via the tyrosine kinase p56lck
142. Tyrosine phosphorylation of P-selectin in intact platelets and in a disulphide-linked complex with immunoprecipitated pp60c-src
143. Platelet endothelial cell adhesion molecule-1 is phosphorylatable by c-Src, binds Src-Src homology 2 domain, and exhibits immunoreceptor tyrosine-based activation motif-like properties
144. Neural cell adhesion molecules modulate tyrosine phosphorylation of tubulin in nerve growth cone membranes
145. Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases
146. Src-related protein tyrosine kinases in hematopoiesis
147. Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions
148. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis
149. Functional overlap in the src gene family: Inactivation of hck and fgr impairs natural immunity
150. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation
151. Profound block in thymocyte development in mice lacking p56lck
152. The cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice
153. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice
154. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease
155. Integrin signal transduction in myeloid leukocytes
156. Resistance to endotoxic shock and reduced neutrophil migration in mice deficient for the Src-family kinases Hck and Fgr
157. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck
158. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn
159. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
160. Src kinases involved in hepatitis B virus replication
161. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras
162. Increase in activity and level of pp60(c-scr) in progressive stages of human colorectal cancer
163. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma
164. Analysis of pp60(c-src) protein kinase activity in human tumor cell lines and tissues
165. Activation of pp60(c-src) protein kinase activity in human colon carcinoma
166. pp60(c-src) Activation in hepatocellular carcinoma of humans and LECS rats
167. c-Src, receptor tyrosine kinases, and human cancer
168. Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas
169. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model
170. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src
171. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
172. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
173. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors
174. Small molecule inhibitors of receptor tyrosine kinases
175. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases
176. SH3 domains and drug design: Ligands, structure, and biological function
177. SH2 and SH3 domains: Choreographers of multiple signaling pathways
178. Peptidomimetic ligands for Src homology-2 domains
179. Src homology-2 domains: Structure, mechanisms, and drug discovery
180. Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain
181. Design of peptidomimetic ligands for the pp60src SH2 domain
182. Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand
183. Structure-based design of novel, dipeptide ligands targeting the pp60Src SH2 domain
184. Potent dipeptide inhibitors of the pp60c-src SH2 domain
185. Structure-activity relationships of a novel class of Src SH2 inhibitors
186. Structure-based design and synthesis of a novel class of Src SH2 inhibitors
187. Covalent binding of catechols to Src family SH2 domains
188. Ligands for the tyrosine kinase p56(lck) SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements
189. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56(lck) SH2 domain
190. NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain
191. Screening of agents which convert 'transformed morphology' of Rous sarcomavirus-infected rat kidney cells to 'normal morphology': Identification of an active agent as herbimycin and its inhibition of intracellular src kinase
192. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60Src in rat kidney cells infected with Rous sarcoma virus
193. Radicicol, an agent inducing the reversal of transformed phenotypes of src-transformed fibroblasts
194. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
195. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
196. Paeciloquinones A, B, C, D, E and F: New potent inhibitors of protein tyrosine kinases produced by Paecilomyces carneus. I. Taxonomy, fermentation, isolation and biological activity
197. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity
198. 1-Methoxyagroclavine from Penicillium sp. WC75209, a novel inhibitor of the Lck tyrosine kinase
199. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors
200. Structural influences of styryl-based inhibitors on epidermal growth factor receptor and p56lck tyrosine-specific protein kinase
201. Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck
202. Aryl amides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors
203. Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck
204. Polyhydroxylated 3-(N-phenyl)carbamoyl-2-iminochromene derivatives as potent inhibitors of tyrosine kinase p60c-src
205. Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors
206. Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors
207. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol
208. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues
209. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src
210. Approach to the discovery of novel, selective inhibitors of p561ck tyrosine kinase: Identification of non-hydroxylated chromones as p56lck inhibitors
211. The development of novel and selective p56lck tyrosine kinase inhibitors
212. Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors
213. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation
214. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both FcepsilonRl- and Thy-1-mediated activation of rat basophilic leukemia cells
215. Structural basis for selective inhibition of Src family kinases by PP1
216. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells: A novel candidate for prevention of vascular remodeling
217. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors
218. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
219. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 08928, a new synthetic protein tyrosine kinase inhibitor
220. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
221. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
222. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
223. Development of a binding model to protein tyrosine kinases for substituted pyrido(2,3-d)pyrimidine inhibitors
224. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
225. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines - Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors
226. Inhibitors of tyrosine kinase
227. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth
228. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
229. Selective inhibition of the tyrosine kinase PP60src by analogs of 5, 10-dihydropyrimido[4,5-b]quinolin-4(1H)-one
230. The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity
231. The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity
232. Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhibitor
233. Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)
234. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors
235. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N-and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners
236. Inhibition of p56lck tyrosine kinase by isothiazolones
237. Benzodiazepine compounds as inhibitors of the src protein tyrosine kinase: Screening of a combinatorial library of 1,4-benzodiazepines
238. Blood platelets express high levels of the pp60(c-scr)-specific tyrosine kinase activity
239. Neurones express high levels of a structurally modified, activated form of pp60c-src
240. Protein tyrosine kinases of the Src family in the central nervous system